Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in New York State

Psychiatric Services

Volumn 60, Issue 12, 2009, Pages 1595-1602

  Essock, Susan M ^a,b   Covell, Nancy H ^c   Leckman Westin, Emily ^c   Lieberman, Jeffrey A ^a,b   Sederer, Lloyd I ^c   Kealey, Edith ^c   Finnerty, Molly T ^a,c  

^a Columbia University ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c NEW YORK STATE OFFICE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CENTRAL STIMULANT AGENT; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE DECANOATE; HALOPERIDOL DECANOATE; HYPNOTIC AGENT; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEDATIVE AGENT; THIORIDAZINE; TRANQUILIZER; VALPROATE SEMISODIUM; VALPROIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BILLING AND CLAIMS; BIPOLAR DISORDER; BIPOLAR I DISORDER; CHILD; CHILD PSYCHIATRY; CLINICAL PRACTICE; CONTROLLED STUDY; DEPRESSION; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICAL EXPERT; MEDICATION ERROR; METABOLIC DISORDER; MONOTHERAPY; PATIENT COMPLIANCE; PRESCRIPTION; SCHIZOPHRENIA; SCREENING TEST; TREATMENT DURATION; UNITED STATES; UTILIZATION REVIEW;

EID: 71549144453     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.2009.60.12.1595     Document Type: Article

References (19)

1. Leckman-Westin E, Finnerty M, Gupta N, et al: Using administrative data to inform prescribing practices: antipsychotic polypharmacy indicator development. Presented at the State Mental Health Agency Services Research, Program Evaluation and Policy Conference, Arlington, Va, Feb 11-13, 2008
2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601, 2004
3. Meyer JM, Davis VG, McEvoy JP, et al: Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1. Schizophrenia Research 103:104-109, 2008
4. American College of Obstetrics and Gynecology Committee on Practice Bulletins-Obstetrics: ACOG Practice Bulletin, no 87, 2007: use of psychiatric medications during pregnancy and lactation. Obstetrics and Gynecology 110:1179-1198, 2007
5. National Collaborating Centre for Mental Health: Antenatal and Postnatal Mental Health: The NICE Guidelines on Clinical Management and Service Guidance. Leicester, United Kingdom, British Psychological Society and the Royal College of Psychiatrists, 2007
6. Joffe H, Cohen LS, Suppes T, et al: Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biological Psychiatry 59:1078-1086, 2006
7. Reproductive Health in Refugee Situations: An Inter-Agency Field Manual. Geneva, Switzerland, World Health Organization, 1999
8. Marder SR, Essock SM, Miller AL, et al: Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 161:1334-1349, 2004
9. Parks J, Radke A, Parker G, et al: Principles of antipsychotic prescribing for policy makers, circa 2008: translating knowledge to promote individualized treatment. Schizophrenia Bulletin 35:931-936, 2009
10. Botts S, Hines H, Littrell R: Antipsychotic polypharmacy in the ambulatory care setting, 1993-2000. Psychiatric Services 54:1086, 2003
11. Faries D, Ascher-Svanum, Zhu B, et al: Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 5:26, 2005
12. Ganguli R, Kotzan JA, Miller LS, et al: Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaideligible schizophrenia patients, 1998-2000. Journal of Clinical Psychiatry 65:1377-1388, 2004
13. Kreyenbuhl JA, Valenstein M, McCarthy JF, et al: Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophrenia Research 84:90-99, 2006 (Pubitemid 43732483)
14. Kreyenbuhl JA, Valenstein M, McCarthy JF, et al: Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatric Services 58:489-495, 2007 (Pubitemid 46640639)
15. Tapp A, Wood AE, Secrest L, et al: Combination antipsychotic therapy in clinical practice. Psychiatric Services 54:55-59, 2003 (Pubitemid 36043847)
16. Tempier RP, Pawliuk NH: Conventional, atypical, and combination antipsychotic prescriptions: a 2-year comparison. Journal of Clinical Psychiatry 64:673-679, 2003
17. Correll CU, Rummel-Kluge C, Corves C, et al: Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophrenia Bulletin 35: 443-457, 2009
18. Josiassen RC, Ashok J, Kohegyi E, et al: Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized double-blind placebo-controlled trial. American Journal of Psychiatry 162:130-136, 2005 (Pubitemid 40095682)
19. Clark RE, Bartels SJ, Mellman TA, et al: Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophrenia Bulletin 228:75-84, 2002